Is LMAT a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for LeMaitre Vascular (LMAT) rests on Price, not volume, is the growth engine: Q2 2026 organic growth of ~10% broke down as ~7% price and ~3% units. The bear case rests on cardiac allograft growth is limited by donor tissue supply, and management is prioritizing US supply before international expansion, so that line stays capacity-bound into the second half of 2026. Analysts covering it publish targets from $81.00 to $132.00 against a $77.01 share price on November 16, 2026, so even the professionals disagree by 51% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

LMAT key stats

At $77.01 on November 16, 2026, LeMaitre Vascular (LMAT) has a market cap of $1.8B, a P/E of 28.0 on trailing earnings (24.4 on forward earnings) and a dividend yield of 1.30%.

Market cap
$1.8B
P/E (trailing)
28.0
P/E (forward)
24.4
EPS (trailing 12 months)
$2.75
Price to book
4.1
Dividend yield
1.30%
Beta
0.49

Market cap, P/E and yield are measured at the $77.01 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with LeMaitre Vascular (LMAT)?

The last two weeks for LeMaitre Vascular, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • LMAT closed at $77.01 on November 16, 2026, down 5.1% over the past five trading days (from $81.16).
  • On November 5, 2026, LeMaitre Vascular filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 4, 2026, LeMaitre Vascular filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
  • On November 5, 2026, Wells Fargo lowered its target to $86.00 from $94.00 (Equal-Weight).
  • On November 5, 2026, Citizens lowered its target to $110.00 from $127.00 (Market Outperform).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

LeMaitre Vascular, founded in 1983 by vascular surgeon George LeMaitre, sells the unglamorous hardware of open vascular surgery: biologic patches, bovine carotid artery grafts sold as Artegraft, human vascular and cardiac allografts, carotid shunts, valvulotomes, embolectomy catheters and synthetic grafts. Roughly 163 direct sales representatives call on vascular surgeons in hospitals, which is the whole point of the model. Individual products are small line items with low average selling prices, too minor for a Medtronic or a Boston Scientific to defend aggressively, so LeMaitre buys niche lines (Restore Flow allografts in 2016 for ~$14M, Artegraft in 2020 for ~$90M), pushes them through its own rep force, and raises prices steadily. The financial result of that approach is a gross margin above 72% and an operating margin near 29%, on trailing revenue of only ~$262M. Trailing net income is ~$65.7M, cash and short-term securities total ~$376M against ~$172.5M of 2.50% convertible notes due February 2030, and the quarterly dividend was raised 25% to $0.25 in February 2026. The June 2026 quarter is where the shine came off: sales of ~$70.4M missed guidance by ~$1.1M on a stronger dollar, Middle East export delays and cardiac allograft tissue supply, and the full-year organic growth target was cut from ~12% to ~11%. Adjusted EPS of ~$0.74 also fell short of the ~$0.81 consensus, the first miss after three quarters of beats. Shares have fallen from a 52-week high of ~$118 to $81.89 at the October 16, 2026 close, down about 19% over three months, up only about 2% year to date and down about 6% over the past year. That puts the multiple near 28 times the ~$2.89 of 2026 guided EPS. Third-quarter results are due November 4, 2026, with consensus near ~$67.4M of sales and ~$0.69 of EPS.

The bull case: what would have to be true for $132.00

The most optimistic published target on LMAT is $132.00, +71.4% from the $77.01 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Price, not volume, is the growth engine

Q2 2026 organic growth of ~10% broke down as ~7% price and ~3% units. Because most LeMaitre products are inexpensive relative to the cost of the procedure they support, list price increases have historically met little hospital resistance. Whether that continues is the single most consequential variable in the model, since a return to mid-single-digit pricing would roughly halve the company's growth rate without any change in surgical volumes.

2. Artegraft going international

The bovine carotid artery graft acquired in 2020 reached ~21% of total sales in Q2 2026 and grew ~34%. Approvals in Vietnam, Morocco and Turkey during the quarter brought the total to 56 countries, international Artegraft sales moved from ~$2.1M in Q1 to ~$2.8M in Q2, and management expects ~$11M of international sales in 2026 against ~$4M in 2025. Filings in Korea, Brazil and India are targeted for 2027.

3. A sales force being expanded into stronger territories

Headcount stood at 163 representatives with a year-end target of 170 to 180, nine already signed for Q3 and 13 openings remaining. The geographic split is telling: EMEA and Asia-Pacific each grew ~18% in the quarter while the Americas grew ~5%, so incremental hiring is aimed where the response has been strongest. Sales capacity, rather than product supply, has been the historic constraint on that expansion.

4. A net cash balance sheet with capital return started

Cash and short-term securities of ~$376M against ~$172.5M of convertible notes leaves roughly $204M of net cash on a ~$1.87B market value (October 2026). A $100M repurchase authorization runs through February 18, 2027 and has gone entirely unused so far. That capacity has historically funded small tuck-in acquisitions of vascular product lines, which is how Artegraft and the allograft operation arrived in the first place.

The bear case: what would have to be true for $81.00

The most pessimistic published target is $81.00, +5.2% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks LeMaitre Vascular is worth if the risks below bite instead of the drivers above.

Cardiac allograft growth is limited by donor tissue supply, and management is prioritizing US supply before international expansion, so that line stays capacity-bound into the second half of 2026. The North Brunswick, New Jersey facility, where the Artegraft graft that now carries ~21% of sales is processed, received additional FDA quality-system observations on June 25, 2026, with a company response filed July 16; an escalation there would reach a large share of revenue. Separately, an FDA pre-submission indicated a clinical trial is likely to be required for the QuickStitch product, on timelines measured in years, and catheter sales fell ~11% against a prior-year period inflated by post-recall stocking orders. Currency, Middle East export disruption and the tissue constraint each accounted for roughly a third of the Q2 revenue shortfall and are expected to persist through the second half. The convertible notes convert near ~$119 to ~$120 per share, which caps upside participation with dilution above that level; as of the latest filings reviewed for this page no filed securities class action, restatement or going-concern matter appears in the company's filings, and the stock's ~28 times guided 2026 earnings (about 26 times 2027 estimates) leaves limited room if pricing power narrows. The September quarter is also a seasonally soft comparison: consensus of ~$0.69 EPS for the November 4 report is below the ~$0.75 of the year-earlier quarter, so a second consecutive miss would land on a stock that has already de-rated.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding LMAT already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on LMAT

7 analysts cover LMAT, with an average target of $99.29 (+28.9% against $77.01) and a split of 4 buy, 4 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the LMAT forecast and price target page.

How is LMAT valued?

Market cap, P/E and dividend yield at today's price are in the LMAT key stats above. The business figures below come from LeMaitre Vascular's reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$262M, up ~10% year over year in Q2 2026
  • Q2 2026 sales: ~$70.4M, ~10% organic (~7% price, ~3% volume)
  • Q2 2026 EPS vs estimate: ~$0.74 vs ~$0.81 consensus
  • Gross / operating margin (TTM): ~71.9% / ~29%
  • FY2026 guidance: sales ~$276.3M, ~11% organic, EPS ~$2.89, operating income ~$76.8M
  • Cash and securities vs debt / dividend: ~$376M vs ~$172.5M converts due 2030; ~$1.00 annual dividend, ~1.2% yield

As of October 2026: At $81.89 a share on October 16, 2026 and a ~$1.87B market value, LMAT carries about 7.1 times trailing sales and roughly 6.4 times sales net of its ~$204M net cash position, with a trailing P/E near 29 and a forward P/E near 26. Those are software-adjacent multiples on a $262M revenue base, sustained by 72% gross margins and a two-decade record of annual price increases rather than by growth (organic growth is guided to ~11%). The de-rating from a ~$118 high to within a few dollars of the 52-week low of ~$78.22 happened on a ~$1.1M revenue miss, an EPS miss and a one-point cut to the organic target, which is a measure of how tightly the valuation was tied to the pricing story holding. Seven covering analysts carry a mean target near $107.

How do you decide if LMAT is a buy?

Whether LMAT is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold LMAT indirectly through an index or sector ETF before adding more.

What would change your mind on LMAT

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: Price, not volume, is the growth engine stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: cardiac allograft growth is limited by donor tissue supply, and management is prioritizing US supply before international expansion, so that line stays capacity-bound into the second half of 2026 fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the LMAT stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about LMAT against your real portfolio and see your actual exposure before deciding.

Your questions about LeMaitre Vascular

Ask Walnut's AI anything about LMAT and see how it fits what you own.

FAQ

Is LMAT a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on Price, not volume, is the growth engine, with revenue (ttm) at ~$262M, up ~10% year over year in Q2 2026. The bear case rests on cardiac allograft growth is limited by donor tissue supply, and management is prioritizing US supply before international expansion, so that line stays capacity-bound into the second half of 2026. Analysts covering it are spread from $81.00 to $132.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell LMAT?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Cardiac allograft growth is limited by donor tissue supply, and management is prioritizing US supply before international expansion, so that line stays capacity-bound into the second half of 2026. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $81.00, +5.2% from the $77.01 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for LMAT?

+

Price, not volume, is the growth engine. Q2 2026 organic growth of ~10% broke down as ~7% price and ~3% units. The most optimistic analyst target on LMAT is $132.00, +71.4% from the $77.01 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for LMAT?

+

Cardiac allograft growth is limited by donor tissue supply, and management is prioritizing US supply before international expansion, so that line stays capacity-bound into the second half of 2026. The North Brunswick, New Jersey facility, where the Artegraft graft that now carries ~21% of sales is processed, received additional FDA quality-system observations on June 25, 2026, with a company response filed July 16; an escalation there would reach a large share of revenue. Separately, an FDA pre-submission indicated a clinical trial is likely to be required for the QuickStitch product, on timelines measured in years, and catheter sales fell ~11% against a prior-year period inflated by post-recall stocking orders. Currency, Middle East export disruption and the tissue constraint each accounted for roughly a third of the Q2 revenue shortfall and are expected to persist through the second half. The convertible notes convert near ~$119 to ~$120 per share, which caps upside participation with dilution above that level; as of the latest filings reviewed for this page no filed securities class action, restatement or going-concern matter appears in the company's filings, and the stock's ~28 times guided 2026 earnings (about 26 times 2027 estimates) leaves limited room if pricing power narrows. The September quarter is also a seasonally soft comparison: consensus of ~$0.69 EPS for the November 4 report is below the ~$0.75 of the year-earlier quarter, so a second consecutive miss would land on a stock that has already de-rated. The most pessimistic published target is $81.00, +5.2% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does LeMaitre Vascular do?

+

LeMaitre Vascular sells the hardware of open vascular surgery: biologic patches, bovine carotid grafts, shunts and catheters, mostly to hospital vascular teams.

What would have to change for LMAT to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Price, not volume, is the growth engine) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (cardiac allograft growth is limited by donor tissue supply, and management is prioritizing US supply before international expansion, so that line stays capacity-bound into the second half of 2026) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does LeMaitre Vascular actually sell?

+

Devices and implants for open vascular surgery: bovine carotid artery grafts (Artegraft), biologic patches, human vascular and cardiac allografts, carotid shunts, valvulotomes, embolectomy catheters and synthetic grafts. About 163 direct representatives sell them to vascular surgeons rather than through distributors in most major markets.

Is LMAT profitable?

+

Yes, and unusually so for its size. The June 2026 quarter produced ~$20.4M of operating income on ~$70.4M of sales, a ~29% operating margin, with a ~72.1% gross margin and ~$17.1M of net income. Trailing twelve-month net income is ~$65.7M on ~$262M of revenue.

Does LMAT pay a dividend?

+

It pays ~$0.25 per quarter, or ~$1.00 annualized, a yield of roughly 1.2% at ~$82 a share (October 2026). The board raised the dividend 25% in February 2026. A separate $100M repurchase authorization runs through February 18, 2027 and had not been used as of the June 2026 quarter.

Walnut is informational, not investment advice, and gives no verdict on LMAT. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks